FDA approved PDE4 inhibitors reduce the dominant toxicity of ALS/FTD associated CHCHD10S59L
Swati Maitra, Minwoo Baek, Yun-Jeong Choe, Nam Chul Kim
The paper shows FDA-approved PDE4 inhibitors reduce mitochondrial defects and toxicity caused by CHCHD10S59L mutations in human cells and Drosophila models.
bioRxiv · Jun 4, 2024 · PreprintNeuroscience